Concert Pharmaceuticals announces CTP-656 solid dose Phase I results confirmed superior pharmacokinetic profile to Kalydeco
Concert is using this tablet formulation of CTP-656 in its ongoing multiple ascending dose Phase I clinical trial and intends to use the same formulation in a Phase II clinical trial.
Concert Pharmaceuticals has announced new results from Part 1 of its multiple ascending dose Phase I clinical trial in which a single-dose tablet formulation of CTP-656 was compared to the commercial tablet formulation of Kalydeco, the current standard of care for cystic fibrosis patients with gating mutations. The results from this study confirmed CTP-656’s superior pharmacokinetic profile to Kalydeco as was previously reported from Concert’s single ascending dose trial, which demonstrated favorable pharmacokinetic properties with an aqueous suspension. Concert is using this tablet formulation of CTP-656 in its ongoing multiple ascending dose Phase I clinical trial and intends to use the same formulation in a Phase II clinical trial. The company is evaluating CTP-656, deuterium-modified ivacaftor, as a novel, potentially disease-modifying treatment for cystic fibrosis as monotherapy as well as in combination with other CFTR modulators.
“We are pleased that the tablet dosage formulation of CTP-656 performed well and confirmed the superior pharmacokinetic profile compared to standard of care. We believe this formulation is suitable for late stage clinical development,” said Roger Tung, President and CEO of Concert Pharmaceuticals. “These CTP-656 results are in line with our goal of providing superior benefits to patients including a more convenient, once-daily medicine that has the potential for improved efficacy.”
Concert has completed Part 1 of a Phase I multiple ascending dose trial to assess CTP-656 in healthy volunteers. Part 1 of the trial, initiated in November 2015, compared a single dose of 150 mg of CTP-656 in a tablet formulation against a single dose 150 mg commercial tablet of Kalydeco in eight subjects, following a high-fat meal. The results confirmed CTP-656’s superior pharmacokinetic profile compared to Kalydeco, including a longer half-life, reduced rate of clearance, substantially increased exposure and greater plasma levels at 24 hours. CTP-656’s half-life of approximately 15 hours supports the potential for once-daily dosing.
With both the solid dose and suspension formulation, the overall metabolite exposure profile of CTP-656 differed from that of Kalydeco. For CTP-656, the greatest exposure in plasma was to parent drug, which is the most active species, whereas with Kalydeco the greatest plasma exposure was to a less-active metabolite.
Part 2 of the multiple ascending dose Phase I trial will assess three doses of CTP-656, ranging between 75 mg and 225 mg, to be administered daily for seven days, compared to placebo. Top-line results are expected in the second quarter of 2016.
Related News
-
News CPHI Frankfurt 2022: Innovator Interview – DSM Biomedical
At CPHI Frankfurt we spoke to Anne-Cecile Bayne, Global Science & Innovation Lead Pharma and Medical Nutrition, and Marc Hendriks, Vice President Strategy & Business Development, on their expertise in nitrosamines and business strategy at DSM Biomedica... -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled. -
News Magic mushrooms could be used to treat mental health conditions
A compound found in magic mushrooms, psilocybin, could be used to treat mental health conditions and help patients suffering with severe depression, as shown by the results of the largest study of its kind to date. -
News UK-based partnership to launch DETERMINE study into rare cancer research
UK-based CRO Quanticate is set to partner with Cancer Research UK for the launch of the DETERMINE study focused on testing a range of existing and approved drugs and therapies on rare cancers. -
News FDA approves Thermo Fisher blood tests for wheat and sesame allergies
Both tests have been approved by the US regulator for in vitro diagnostic use -
News QIAGEN launches world’s first syndromic test for monkeypox
The test can distinguish between monkeypox and other diseases that cause similar symptoms. -
News Monkeypox Update: Vaccine shortage, sewage surveillance and global testing
As concern over the monkeypox outbreak continues to rise, we take a look at major developments from the first week of August. -
News CPHI Podcast Series: The importance of novel excipients for innovative drug development
The latest episode in the CPHI Podcast Series dives into the world of novel excipients and explores their importance for innovative drug development.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance